Brexit’s Disruptive Impact On U.K. And European Prescription Drug Market

In brief, a no-deal Brexit would imply an unprecedented disruption of the European pharmaceuticals market in terms of research, regulation, manufacture, and trade in biopharmaceuticals. It would even impact drug prices as reference pricing schemes throughout the E.U. would need to be altered.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive